Eris Lifesciences Limited
Symbol: ERIS.NS
NSE
843.7
INRTrhová cena dnes
29.8535
Pomer P/E
2.0937
Pomer PEG
114.78B
MRK Cap
- 0.00%
Výnos DIV
Eris Lifesciences Limited (ERIS-NS) Finančné výkazy
Súvaha
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 5613.44 | 892.4 | 1772.4 | 522.7 | |||||||||||
balance-sheet.row.short-term-investments | 6124.75 | 332.2 | 1264.5 | 154 | |||||||||||
balance-sheet.row.net-receivables | 6515.97 | 2966.9 | 2260.9 | 2280.6 | |||||||||||
balance-sheet.row.inventory | 2705.24 | 1314.3 | 1179.1 | 944.7 | |||||||||||
balance-sheet.row.other-current-assets | 5222.75 | 2473.5 | 1060.8 | 922.5 | |||||||||||
balance-sheet.row.total-current-assets | 20057.4 | 7647.2 | 6273.3 | 4670.5 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 7998.42 | 3773.8 | 1918.6 | 778.8 | |||||||||||
balance-sheet.row.goodwill | 6636.98 | 3318.5 | 934.7 | 934.7 | |||||||||||
balance-sheet.row.intangible-assets | 37042.03 | 18806 | 6596 | 6840.8 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 43679.01 | 22124.5 | 7530.7 | 7775.5 | |||||||||||
balance-sheet.row.long-term-investments | 16.43 | 68.8 | 4208.4 | 2859.2 | |||||||||||
balance-sheet.row.tax-assets | 5690.48 | 2739.4 | 2431.3 | 2006.3 | |||||||||||
balance-sheet.row.other-non-current-assets | -2016.58 | 319.6 | 359 | 257.6 | |||||||||||
balance-sheet.row.total-non-current-assets | 55367.76 | 29026.1 | 16448.1 | 13677.3 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 75425.16 | 36673.3 | 22721.4 | 18347.8 | |||||||||||
balance-sheet.row.account-payables | 2752.94 | 1247.7 | 1177.7 | 1026.2 | |||||||||||
balance-sheet.row.short-term-debt | 3903.21 | 1932.9 | 40.1 | 23.3 | |||||||||||
balance-sheet.row.tax-payables | 176.96 | 39 | 70 | 77.5 | |||||||||||
balance-sheet.row.long-term-debt-total | 13158.94 | 6834.2 | 803.9 | 44.5 | |||||||||||
Deferred Revenue Non Current | 623.49 | 87.4 | 56.9 | 61.1 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 5109.42 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 438.6 | 217.2 | 152.4 | 132.5 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 19538.95 | 10034.2 | 1642.9 | 914.3 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 903 | 466.9 | 394 | 67.7 | |||||||||||
balance-sheet.row.total-liab | 28942.66 | 14466.5 | 3639.4 | 2583.6 | |||||||||||
balance-sheet.row.preferred-stock | 21930.12 | 21930.1 | 19062.4 | 15722.7 | |||||||||||
balance-sheet.row.common-stock | 272.01 | 136 | 135.9 | 135.8 | |||||||||||
balance-sheet.row.retained-earnings | 21559.3 | 21559.3 | 18736.5 | 15503.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 70084.98 | 29.8 | 20.7 | 41.5 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | -21288.35 | -21695.3 | -18872.5 | -15638.9 | |||||||||||
balance-sheet.row.total-stockholders-equity | 92558.06 | 21959.9 | 19083.1 | 15764.2 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 121907.66 | 36673.3 | 22721.4 | 18347.8 | |||||||||||
balance-sheet.row.minority-interest | 406.94 | 246.9 | -1.1 | 0 | |||||||||||
balance-sheet.row.total-equity | 92965 | 22206.8 | 19082 | 15764.2 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 121907.66 | - | - | - | |||||||||||
Total Investments | 5883.66 | 143.5 | 4208.4 | 2436.4 | |||||||||||
balance-sheet.row.total-debt | 17062.15 | 8767.1 | 844.1 | 67.8 | |||||||||||
balance-sheet.row.net-debt | 17573.46 | 8206.9 | 336.1 | -300.9 |
Výkaz peňažných tokov
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 3864.39 | 4046.4 | 4422 | 3945 | |||||||||||
cash-flows.row.depreciation-and-amortization | 1638.34 | 1170.9 | 647 | 429.9 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | -809.7 | -976.6 | -670.9 | |||||||||||
cash-flows.row.stock-based-compensation | 31.21 | 31.2 | 13.6 | 11.2 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | -1755.4 | -299 | 53.3 | |||||||||||
cash-flows.row.account-receivables | 0 | -1171.4 | -204.8 | 159 | |||||||||||
cash-flows.row.inventory | 0 | 47.4 | -234.4 | -249.9 | |||||||||||
cash-flows.row.account-payables | 0 | -105 | 151.6 | 25.7 | |||||||||||
cash-flows.row.other-working-capital | 0 | -526.5 | -11.3 | 118.6 | |||||||||||
cash-flows.row.other-non-cash-items | -3895.6 | 233.9 | -24.4 | -14.7 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 2605.29 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -8414.2 | -1210.3 | -257.6 | |||||||||||
cash-flows.row.acquisitions-net | 0 | -6554.9 | -103 | -2.8 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -300 | -2677.7 | -3733.9 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 5204.4 | 795.9 | 774.2 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 243.7 | -1 | -13.4 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -9821 | -3196.1 | -3233.6 | |||||||||||
cash-flows.row.debt-repayment | 0 | -3500 | -450 | -0.1 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 22.8 | 67.5 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 3477.2 | -450 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | -999.1 | -816.2 | -746.8 | |||||||||||
cash-flows.row.other-financing-activites | 0 | 7879.4 | 1201.8 | -77.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 6880.3 | -447 | -824 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 74.9 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 2605.29 | 51.5 | 139.6 | -303.9 | |||||||||||
cash-flows.row.cash-at-end-of-period | 6306.92 | 560.2 | 508.7 | 369.1 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 3701.63 | 508.7 | 369.1 | 673.1 | |||||||||||
cash-flows.row.operating-cash-flow | 2605.29 | 2917.4 | 3782.6 | 3753.6 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -8414.2 | -1210.3 | -257.6 | |||||||||||
cash-flows.row.free-cash-flow | 2605.29 | -5496.8 | 2572.3 | 3496 |
Riadok výkazu ziskov a strát
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 18406.22 | 16618.2 | 13261.7 | 11926.4 | |||||||||||
income-statement-row.row.cost-of-revenue | 3346.18 | 3523.5 | 2608.1 | 2418.7 | |||||||||||
income-statement-row.row.gross-profit | 15060.04 | 13094.7 | 10653.6 | 9507.8 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 61 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 1189.54 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 63.85 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 96.71 | 111.5 | 10.4 | 4.5 | |||||||||||
income-statement-row.row.operating-expenses | 10245.46 | 8898.1 | 6403 | 5620 | |||||||||||
income-statement-row.row.cost-and-expenses | 13591.64 | 12421.6 | 9011.1 | 8038.7 | |||||||||||
income-statement-row.row.interest-income | 402.19 | 23 | 61 | 22.9 | |||||||||||
income-statement-row.row.interest-expense | 606.36 | 261.7 | 41.5 | 18 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 63.85 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -596.47 | -170.2 | 176.9 | 68.9 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 96.71 | 111.5 | 10.4 | 4.5 | |||||||||||
income-statement-row.row.total-operating-expenses | -596.47 | -170.2 | 176.9 | 68.9 | |||||||||||
income-statement-row.row.interest-expense | 606.36 | 261.7 | 41.5 | 18 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 1638.34 | 1170.9 | 647 | 429.9 | |||||||||||
income-statement-row.row.ebitda-caps | 6549.63 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 4901.4 | 4216.6 | 4245 | 3876.1 | |||||||||||
income-statement-row.row.income-before-tax | 4304.93 | 4046.4 | 4422 | 3945 | |||||||||||
income-statement-row.row.income-tax-expense | 515.94 | 304.8 | 364.1 | 393.6 | |||||||||||
income-statement-row.row.net-income | 3864.39 | 3821.6 | 4061.1 | 3551.3 |
Často kladené otázky
Čo je Eris Lifesciences Limited (ERIS.NS) celkové aktíva?
Eris Lifesciences Limited (ERIS.NS) celkové aktíva sú 36673280000.000.
Aký je ročný obrat podniku?
Ročné príjmy sú 9840010000.000.
Aké je ziskové rozpätie podniku?
Zisková marža firmy je 0.818.
Aký je voľný peňažný tok podniku?
Voľný peňažný tok je 19.153.
Aká je čistá zisková marža podniku?
Čistá zisková marža je 0.210.
Aké sú celkové výnosy podniku?
Celkové príjmy sú 0.266.
Aká je Eris Lifesciences Limited (ERIS.NS) čistý zisk (čistý príjem)?
Čistý zisk (čistý príjem) je 3821580000.000.
Aký je celkový dlh firmy?
Celkový dlh je 8767110000.000.
Aké je číslo prevádzkových nákladov?
Prevádzkové výdavky sú 8898080000.000.
Aký je údaj o hotovosti spoločnosti?
Peňažné prostriedky podniku sú -1906240000.000.